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Abstract: The NLRP3 inflammasome is an important regulator of the 
sterile inflammatory response and its activation by host-derived sterile 
molecules leads to the intracellular activation of caspase-1, 
processing of the pro-inflammatory cytokines interleukin-1β (IL-1β)/IL-
18, and pyroptotic cell death. Inappropriate activation of NLRP3 drives 
a chronic inflammatory response and is implicated in several non-
communicable diseases, including gout, atherosclerosis, type II 
diabetes and Alzheimer’s disease. In this study, we report the design, 
synthesis and biological evaluation of novel boron compounds (NBCs) 
as NLRP3 inflammasome inhibitors. Structure-activity relationships 
(SAR) show that 4-F groups on the phenyl rings retain NLRP3 
inhibitory activity, whereas more steric and lipophilic substituents 
diminish activity. Loss of inhibitory activity is also observed when the 
CCl3 group on the oxazaborine ring is replaced by a CF3 group. These 
findings provide additional understanding of the NBC series and will 
aid in the development of these NLRP3 inhibitors as tool compounds 
or therapeutic candidates for sterile inflammatory diseases. 
Introduction 
Sterile inflammation is a host-driven immune response to injury in 
the absence of infection.[1] A central regulator of the sterile 
inflammatory response is the NOD-like receptor, pyrin domain-
containing protein 3 (NLRP3), a soluble pattern recognition 
receptor (PRR) whose activation facilitates release of the pro-
inflammatory cytokines interleukin-1β (IL-1β) and IL-18 by forming 
a multiprotein complex called the NLRP3 inflammasome.[2,3] 
NLRP3 is activated by various stimuli, including host-derived 
endogenous molecules released by necrosis termed damage-
associated molecular patterns (DAMPs).[2,3] Given the structural 
diversity of its known agonists, it is unlikely that known DAMPs 
engage NLRP3 directly[4] and there have been several proposed 
mechanisms for NLRP3 activation which converge on a two-step 
signalling process.[5,6] The first step is referred to as priming, and 
an initial stimulus (e.g. a TLR ligand) is required to upregulate the 
intracellular levels of NLRP3 and pro-IL-1β. The second step is 
termed activation in which the primed cell encounters a second 
stimulus (e.g. a NLRP3 activating DAMP) that leads to NLRP3 
inflammasome formation. This process is ATP-dependent and 
requires the association of NLRP3 with the adaptor protein 
apoptosis associated speck-like protein containing a CARD 
(ASC). The inactive zymogen pro-caspase-1 is then recruited to 
the NLRP3 inflammasome via CARD-CARD homotypic 
interactions with ASC, resulting in its proximity-induced 
autocleavage into active caspase-1. Caspase-1 then cleaves pro-
IL-1β/IL-18 into their biologically active mature forms IL-1β/IL-18 
which are subsequently released from the cell into the 
extracellular space where they drive an inflammatory response.[4-
7] Activation of caspase-1 also leads to a form of cell death termed 
pyroptosis.[4]    
IL-1β and NLRP3 activation are well characterised in a 
number of non-communicable diseases involving sterile 
inflammation including gout,[8] atherosclerosis[9] and type II 
diabetes (T2D).[10,11] Neuroinflammation caused by microglial 
activation is also often dependent on NLRP3 and IL-1β and is 
associated with depression[12] and Alzheimer’s disease (AD).[13,14] 
Gain-of-function mutations in the NLRP3 gene causes 
spontaneous IL-1β release in patients with cryopyrin-associated 
periodic syndrome (CAPS) diseases that are characterised by 
fever, rashes and extensive joint pain.[15]  
Given the critical role of NLRP3 and IL-1β in human 
disease,[16] there has been great interest in the development of 
pharmacological agents that target the NLRP3-IL-1β axis. 
Although anti-IL-1β therapy using the biological IL-1β inhibitors 
rilonacept (Arcalyst), canakinumab (Ilaris) and anakinra (Kineret) 
are highly effective and are currently used clinically, blockade of 
NLRP3 inflammasome activation would offer distinct advantages. 
Firstly, biological IL-1β inhibitors are only able to target IL-1β 
whereas small molecule NLRP3 inhibitors are likely to inhibit both 
IL-1β and IL-18 release, block pyroptosis,[17] and prevent the 
secretion of inflammasome components that are themselves pro-
inflammatory.[18,19] Secondly, biological IL-1β inhibitors are 
protein-based therapeutics that are expensive, with anakinra 
requiring high dosages and frequent administration.[20] 
Additionally, they are unlikely to cross the blood-brain barrier 
(BBB) easily and thus are limited to peripheral inflammatory 
diseases. Therefore it would be preferable to develop small 
molecule therapeutics capable of blocking NLRP3 inflammasome 
activation as they could be of use for CNS indications, are able to 
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be administered orally and are likely to be more cost-effective 
alternatives. 
A number of small molecule inhibitors of the NLRP3 
inflammasome have been previously described.[21] However, 
many of the reported small molecule NLRP3 inhibitors have 
potency in the micromolar range, show poor selectivity or contain 
reactive functional groups, limiting their development as potential 
drug candidates. A notable exception is MCC950 (formerly known 
as CRID3 or CP-456,773), the most potent and selective inhibitor 
of the NLRP3 inflammasome to date,[22] and its hybrids with known 
sulfonylurea drugs are being developed as dual action insulin 
secretagogues and NLRP3 inhibitors for T2D.[23] There is also 
commercial interest in the development of sulfonylurea drugs as 
NLRP3 inflammasome inhibitors, with recent patents in the 
sulfonylurea space highlighting the significant current interest in 
the NLRP3 inhibitor area.[24,25] Nevertheless, there is still a need 
for new NLRP3 inhibitors as there are currently no approved small 
molecule inhibitors of the NLRP3 inflammasome available 
clinically. 
We recently reported on the discovery of new boron-based 
small molecules as potent NLRP3 inhibitors.[26] Three of the 
oxazaborine compounds screened, BC7 (1), BC23 (2) and NBC6 
(3, Figure 1) were particularly effective inhibitors of IL-1β release. 
The pharmacophore for these molecules responsible for NLRP3 
inhibition is the oxazaborine ring and the highly electron-
withdrawing trichloromethyl (CCl3) group. However, the impact of 
phenyl ring substitutions on IL-1β release was not assessed. 
Additionally, the presence of the CCl3 group significantly 
contributes to the high lipophilicity of these oxazaborine inhibitors, 
limiting their drug-likeness.  
Here we explored structure-activity relationships (SAR) of 
phenyl ring substitutions based on the known NLRP3 inhibitors 
BC23 (2) and NBC6 (3), in addition to seeking alternative 
bioisosteres of the CCl3 group in the search for new NLRP3 
inhibitors with improved potency and drug-like properties. 
 
 
 
Figure 1. Boron-based NLRP3 inflammasome inhibitors. 
Results and Discussion 
Chemistry 
 
Using the Topliss scheme for aromatic substituents,[27] a series of 
mono- and di-substituted oxazaborine novel boron compounds 
(NBCs) were synthesised by considering both lipophilicity and 
electronic factors in order to determine the optimal substituent as 
efficiently as possible. Borinic acids with identical substituted 
phenyl rings (Scheme 1, Method A) were first synthesised by 
reacting two molar equivalents of an aryl halide (4, X = MgBr, Br 
or I) with magnesium turnings or isopropylmagnesium chloride 
(iPrMgCl), followed by treatment with one molar equivalent of 
trimethyl borate (B(OMe)3) to afford symmetrical borinic acids 
(5).[28] Alternatively, mono-substituted aryl(phenyl)borinic acids 
(Scheme 1, Method B) were synthesised by treating 4 (when X = 
MgBr), such as p-tolylmagnesium bromide, with a stoichiometric 
quantity of phenylboronic acid pinacol ester (7) to give the 
asymmetric borinic acid (6).  
The synthesised borinic acids 5 and 6 were then reacted with 
either (Z)-2-acetyl-3-amino-4,4,4-trichlorobut-2-enamide or (Z)-4-
amino-5,5,5-trichloropent-3-en-2-one[26] at 50 oC in THF to give 
substituted NBC6 (NBC32-33 and NBC40) or BC23 analogues 
(NBC35-39), respectively (Scheme 1).  
AN0128, a known borinic acid picolinate ester prepared by 
Anacor Pharmaceuticals, was also synthesised in a two-step 
method according to the reported procedure (Scheme 1, 
Method A).[29] The rationale for the synthesis of AN0128 was due 
to its structural similarity with our oxazaborine inhibitors, in 
addition to its known potent anti-bacterial and anti-inflammatory 
activities. AN0128 showed 99% inhibition of IL-1β release and 
100% inhibition of TNF-α release from human LPS-induced 
PBMCs at a concentration of 10 µM,[29] and has since entered 
Phase II clinical trials for the treatment of atopic dermatitis, acne 
and periodontal disease.[30] Therefore it was of interest to compare 
the inhibitory activity of the oxazaborine derivatives with AN0128 
in the IL-1β release assay.  
Although the synthesis of oxazaborine derivatives containing 
electron-donating substituents (R = R1 = 4-OMe, 4-NMe2, 
Scheme 1) were attempted, we found that the bromine-
magnesium (Br-Mg) exchange reaction of aryl bromides with 
B(OMe)3 was highly dependent on aromatic ring substitution. 
Electron-withdrawing aryl halides (R = R1 = 4-F, 4-Cl, 4-CF3, 3,4-
Cl2, Scheme 1) generally reacted well with magnesium turnings 
to give the corresponding borinic acids after aqueous work-up. In 
contrast, electron-donating substituents (R = R1 = 4-CH3, 4-OMe, 
4-NMe2, Scheme 1) caused the aryl bromide to react very slowly 
with magnesium turnings and, for 4- bromoanisole and 4-bromo-
N,N-dimethylaniline, led to a number of side-products. The lack of 
significant reactivity observed for electron-rich aryl bromides 
towards Br-Mg exchange is in line with previous reports.[31,32] 
Analogues of BC23 (2) and NBC6 (3) were then designed 
where the CCl3 group was replaced with the bioisosteric 
trifluoromethyl (CF3) group (Scheme 2). We had previously shown 
that only electron-withdrawing substituents at this position were 
effective NLRP3 inhibitors,[26] thus the CF3 moiety should retain 
similar electron-withdrawing properties to that of a CCl3 group but 
is significantly less lipophilic. Additionally, replacement of the 
polychlorinated centre would rule out its potentially labile nature 
with regards to attack by nucleophiles or radicals.  
CF3CN was prepared from trifluoroacetamide using 
trifluoroacetic anhydride according to the method described by 
Parker.[33] CF3CN was reacted with either acetylacetone or 
acetoacetamide to give 8 and 9, respectively (Scheme 2). 
Intermediate 8 was deacetylated under basic conditions using a 
saturated solution of K2CO3 in EtOH to give deacetylated β-
trifluoroenaminone 10.[34] Subsequently, intermediates 9 and 10 
were borylated with diphenylborinic anhydride (DPBA) to give 
analogues NBC41 and NBC42 (Scheme 2). 
 
Inhibition of IL-1β release 
 
We initially tested the effect of modifying the phenyl rings of NBCs 
on their ability to inhibit NLRP3 inflammasome-dependent 
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Scheme 1. Synthesis of 2,2-diaryl-1,3,2-oxazaborines (NBC32-40) and AN0128. Reagents and conditions: a) B(OMe)3, THF, r.t., 3 h (when X = MgBr); b) Mg, I2, 
B(OMe)3, THF, 40 oC, 3 h (when X = Br); c) iPrMgCl, B(OMe)3, THF, 0 oC to r.t., 16 h (when X = I); d) 4 (X = MgBr), THF, r.t., 3 h; e) (Z)-4-Amino-5,5,5-trichloropent-
3-en-2-one or (Z)-2-acetyl-3-amino-4,4,4-trichlorobut-2-enamide, THF, 50 oC, 16 h; f) 3-Hydroxypicolinic acid, EtOH, reflux, 15 mins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of trifluoromethyl derivatives of BC23 (NBC41) and NBC6 
(NBC42). Reagents and conditions: a) CF3CN, Zn(acac)2, DCM, r.t., 18 h; b) 
K2CO3, EtOH, 50 oC, 24 h (when R = Me); c) DPBA, THF, 50 oC, 16 h. 
 
release of IL-1β from macrophages. Immortalized bone marrow 
derived macrophages (iBMDMs) were treated with LPS (1 µg/ml, 
4 h) to prime the cells and induce expression of pro-IL-1β. The 
primed cells were then incubated with vehicle (0.5% DMSO) or 
inhibitor (10 µM) for 15 minutes before the NLRP3 inflammasome 
activator nigericin (10 µM, 1 h) was added to cells. Supernatants 
were removed and IL-1β levels were analysed by ELISA. 
Nigericin induced release of IL-1β and this was inhibited by our 
parent molecule BC23 as expected (Figure 2A). Addition of a 
small electron withdrawing fluorine at the para position of each 
phenyl ring (NBC35) had minimal effect on inhibitory activity 
(Figure 2A). However, inhibitory activity was reduced when 
bulkier, more lipophilic substituents were added (Figure 2A, 
NBC36-40). The electron-withdrawing properties of aryl 
substituents were insignificant for inhibitory activity as the 
bioisosteric 4-Cl (NBC36), 4-CF3 (NBC37) and 4-CH3 (NBC38) 
derivatives all inhibited IL-1β release to a similar extent. This 
observation is further supported by the significantly reduced 
activities of 3,4-Cl2 (NBC39) and 3-Cl,4-Me (NBC40) derivatives 
which possess additional substitutions around the phenyl rings. In 
contrast, there was an observed correlation between increasing 
lipophilicity and decreasing inhibitory activity across the BC23 
series (NBC35 < NBC36 ~ NBC37 ~ NBC38 < NBC39). These 
observations were also in agreement across the NBC6 series, 
where the di-substituted-p-tolyl analogue NBC32 had slightly 
reduced IL-1β inhibitory activity compared to the mono-
substituted-p-tolyl analogue NBC33 and parent compound NBC6 
in THP-1 cells (Figure S1). These results suggest that aryl ring 
substitution, particularly with more steric and lipophilic 
substituents, is unlikely to enhance the activity of the NBCs. 
It was surprising to note the lack of inhibitory activity of 
AN0128 in the IL-1β release assay given its known anti-
inflammatory effects against IL-1β and TNF-α.[29] This could be 
Compound R R1 R2 R3 Compound R R1 R2 R3 
NBC32 4-Me 4-Me NH2 COMe NBC37 4-CF3 4-CF3 Me H 
NBC33 4-Me H NH2 COMe NBC38 4-Me 4-Me Me H 
NBC35 4-F 4-F Me H NBC39 3,4-Cl2 3,4-Cl2 NH2 COMe 
NBC36 4-Cl 4-Cl Me H NBC40 3-Cl-4-Me 3-Cl-4-Me NH2 COMe 
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Figure 2: Effects of the new NBCs on IL-1β release. iBMDMs were treated with LPS (1 µg/ml, 4 h) followed by vehicle or drugs with ring substitutions (BC23 vs 
NBC35-40, AN0128) (A), or drugs with CCl3 substituted for CF3 (BC23 vs NBC41; NBC6 vs NBC42) (B). Drugs were incubated at 10 µM 15 min before stimulation 
with nigericin (10 µM, 1 h). IL-1β was measured by ELISA. Data are presented as the mean ± s.e.m. with a minimum of 3 experiments per group. Ns = non-significant, 
*=P<0.05, ***=P<0.001, vs vehicle. 
 
due to differences in cell type (iBMDMs vs PBMCs) or the two-
step priming and activating stimuli used in this study compared to 
a single LPS stimulus used previously.[29] Nevertheless, the 
observation that AN0128 had little effect on IL-1β release in our 
NLRP3 inflammasome-dependent assay is an important finding 
and suggests that the anti-inflammatory action of AN0128 is 
independent of blocking NLRP3 inflammasome activation. 
We then tested the effects of BC23 and NBC6 analogues 
where the CCl3 group had been replaced with the bioisosteric 
trifluoromethyl (CF3) group (Scheme 2). As we had previously 
reported that only electron-withdrawing substituents at this 
position were effective NLRP3 inhibitors,[26] we proposed that 
substituting CCl3 for a CF3 group would test the importance of 
lipophilicity whilst retaining similar electron-withdrawing 
properties. Using the iBMDM model as described, nigericin 
induced a significant release of IL-1β and this was inhibited by 
BC23 and NBC6 (Figure 2B). However, both NBC41 (the CF3 
analogue of BC23) and NBC42 (the CF3 analogue of NBC6) were 
ineffective under these conditions (Figure 2B). These results, 
together with our previous observations, clearly demonstrate that 
the CCl3 group fulfils both the lipophilic and electron-withdrawing 
properties required at this position that is critical for the inhibitory 
effects of the NBCs in the IL-1β release assay (Figure 2B).  
Given that the CCl3 group is essential for IL-1β inhibitory 
activity, preliminary chemical studies on BC23 to determine the 
potential lability of the CCl3 group to cysteine, amine-based and 
oxygen-based nucleophiles were performed. However, no 
evidence of CCl3 modification or loss was observed, except 
fragmentation under mass spectrometry conditions (data not 
shown). Therefore these initial studies suggest that the CCl3 
group is not labile under these reaction conditions. It was noted 
that during these experiments, nucleophiles were found to attack 
the boron atom and undergo decomplexation. For example, BC23 
cleanly hydrolyses into diphenylborinic acid and (Z)-4-amino-
5,5,5-trichloropent-3-en-2-one in 9:1 DMSO-d6/D2O solvent at 
37 oC with a half-life of ~24 h, as monitored by 1H NMR 
spectroscopy (Figure S2). 
Conclusions 
The NLRP3 inflammasome is a multi-molecular protein 
complex that is critical for inflammatory responses. Its formation 
leads to activation of caspase-1, which cleaves and activates IL-
1β.[5]  NLRP3 inflammasome activation is suggested to be 
important in diseases such as Alzheimer’s disease,[13] 
atherosclerosis,[9] and metabolic disease such as type II 
diabetes.[10] The importance of IL-1β to disease was further 
highlighted following the recent publication of the CANTOS trial, 
where patients with a history of myocardial infarction were treated 
with canakinumab, a monoclonal antibody targeting IL-1β.[35] It 
was found that canakinumab treatment reduced the rate of 
recurrent cardiovascular events, and cancer mortality, in addition 
to many other clinical outcomes.[35] The CANTOS findings have 
since led to several pharmaceutical companies seeking to 
develop molecules that target NLRP3 directly.[36] There is thus a 
growing interest in inhibitors of the NLRP3 inflammasome.[21]  
We recently published the NBC series of NLRP3 
inflammasome inhibitors reporting that key features required for 
bioactivity were the oxazaborine ring and CCl3 group.[26] Here we 
have further refined the SAR and shown that substitutions on the 
aryl rings do not enhance inhibitory activity, and that the 
lipophilicity of the CCl3 group is key to inhibitory activity. These 
discoveries provide new insights into the activity of the NBC series 
and will aid future development of the NBC molecules as 
inflammasome inhibitors. 
Experimental Section 
Chemistry 
General: (Z)-4-Amino-5,5,5-trichloropent-3-en-2-one and (Z)-2-acetyl-3-
amino-4,4,4-trichlorobut-2-enamide intermediates were prepared as 
previously described.[26] All other chemicals, solvents and deuterated 
solvents were purchased from Sigma-Aldrich, Alfa-Aesar or Fisher 
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Scientific. 1H, 13C, 11B and 19F NMR spectra were recorded on a Bruker 
Avance 400 or 300 MHz spectrometer. Chemical shifts (δ) are defined in 
parts per million (ppm). 1H NMR spectra were referenced to 
tetramethylsilane (TMS, δ = 0.0 ppm) or residual undeuterated solvent 
(CDCl3, δ = 7.26 ppm; DMSO-d6, δ = 2.50 ppm). 13C NMR spectra were 
referenced to residual undeuterated solvent (CDCl3, δ = 77.16 ppm, 
DMSO-d6 = 39.52 ppm) as an internal reference. 11B NMR chemical shifts 
were referenced to external reference BF3.OEt2 (δ = 0.0 ppm). 19F NMR 
chemical shifts were referenced using the deuterium lock signal of the 
solvent. ESI and APCI mass spectrometry was carried out on a Waters 
Acquity UPLC system connected to a Waters SQD2 mass spectrometer. 
Accurate mass determination was carried out on a Thermo Exactive™ 
Plus EMR Orbitrap™ LC-MS system. Molecular ion peaks are defined as 
mass/charge (m/z) ratios. Infrared spectroscopy was recorded on a 
JASCO FT/IR-4100 spectrophotometer using the Spectra Manager II 
(JASCO) software package. Melting points were measuring using a Stuart 
SMP10 melting point apparatus. Lyophilisation was carried out using a 
Christ alpha1-4 plus freeze dryer equipped with an Edwards vacuum pump. 
Microwave irradiation was carried out on a Biotage® Initiator Classic 
microwave using 2-5 mL Biotage® glass vials. Analytical thin-layer 
chromatography (TLC) was performed using silica gel 60 on aluminium 
sheets coated with F254 indicator. All spots were visualised with KMnO4 
or ultraviolet light using a MV Mineralight lamp (254/365) UVGL-58. Flash 
column chromatography was performed using silica gel with particle size 
40-63 μm. Evaporation of solvents was conducted on a Buchi Rotavapor 
R-200. 
Di-p-tolylborinic acid (5a): To an oven-dried Schlenk flask under N2 was 
added p-tolylmagnesium bromide (1.0 M in THF, 9.98 mL, 10 mmol) in 
anhydrous THF (5 mL). B(OMe)3 (0.55 mL, 5 mmol) was added dropwise 
to the reaction mixture and stirred at room temperature for 3 h. 1M HCl (10 
mL) was then added and stirred for 30 mins to quench the reaction. The 
reaction mixture was extracted with EtOAc (3 x 10 mL), washed with brine 
(1 x 10 mL), dried over MgSO4, filtered and evaporated in vacuo. The crude 
product was then purified by flash column chromatography (EtOAc/n-
hexane, 1:19) to give 5a as a colourless oil (0.61 g, 58%). 1H NMR 
(300 MHz, CDCl3): δ = 7.63 (d, J = 7.8 Hz, 4H, B-Ar(m)), 7.18 (d, J = 7.5 Hz, 
4H, B-Ar(o)), 5.65 (br s, 1H, OH), 2.33 ppm (s, 6H, CH3 x 2); 13C NMR 
(75 MHz, CDCl3): δ = 141.2 (B-Ar(p)), 134.8 (B-Ar(o)), 128.7 (B-Ar(m)), 
21.7 ppm (CH3), B-Ar(i) quaternary signal not observed. 
5-Acetyl-6-amino-2,2-bis(p-tolyl)-4-(trichloromethyl)-2,3-dihydro-
1,3,2-oxazaborinin-1-ium-2-uide (NBC32): (Z)-2-Acetyl-3-amino-4,4,4-
trichlorobut-2-enamide (1.46 g, 5.95 mmol) was added to a solution of 5a 
(0.50 g, 2.38 mmol) in anhydrous THF (5 mL). The mixture was stirred at 
50 oC under N2 for 16 h. The mixture was concentrated in vacuo and 
purified by flash column chromatography (EtOAc/n-hexane, 2:23). The 
collected fractions were combined, evaporated in vacuo and stirred in cold 
n-hexane (15 mL) for 30 min. The precipitate was then filtered and dried 
under vacuum to give NBC32 as a yellow solid (0.14 g, 14%). mp: 145-
148 oC (dec); 1H NMR (300 MHz, CDCl3): δ = 9.23 (br s, 1H, CONH2), 7.58 
(br s, 1H, Cl3C(NH)C=C), 7.29 (d, J = 7.5 Hz, 4H, B-Ar(o)), 7.12 (d, 7.5 Hz, 
4H, B-Ar(m)), 5.92 (br s, 1H, CONH2), 2.34 (s, 6H, CH3 x 2), 2.32 ppm (s, 
3H, CH3CO); 13C NMR (75 MHz, CDCl3): δ = 198.1 (CH3CO), 169.2 
(CONH2), 165.5 (Cl3C(NH)C=C), 156.1 (B-Ar(i)), 136.2 (B-Ar(p)), 132.0 (B-
Ar(o)), 128.2 (B-Ar(m)), 97.9 (Cl3C(NH)C=C), 94.5 (CCl3), 34.0 (CH3CO), 
21.3 ppm (CH3); IR (neat): 3388 (N-H), 3313 (N-H), 1644 (C=O), 1608 
(C=C, conjugated), 1561 (C=C-NH) cm-1; MS(ES-) (m/z): 434.2 [M-H, 10B, 
35Cl, 35Cl, 35Cl, 12%]-, 435.2 [M-H, 11B, 35Cl, 35Cl, 35Cl, 100%]-, 436.2 [M-H, 
10B, 35Cl, 35Cl, 37Cl, 24%]-, 437.2 [M-H, 11B, 35Cl, 35Cl, 37Cl, 50%]-, 438.2 
[M-H, 10B, 35Cl, 37Cl, 37Cl, 11%]-, 439.2 [M-H, 11B, 35Cl, 37Cl, 37Cl, 10%]-; 
MS(ES+) (m/z): 344.1 [M-Tolyl, 10B, 35Cl, 35Cl, 35Cl, 10%]+, 345.0 [M-Tolyl, 
11B, 35Cl, 35Cl, 35Cl, 27%]+, 346.0 [M-Tolyl, 10B, 35Cl, 35Cl, 37Cl, 12%]+, 347.0 
[M-Tolyl, 11B, 35Cl, 35Cl, 37Cl, 36%]+, 349.1 [M-Tolyl, 11B, 35Cl, 37Cl, 37Cl, 
21%]+, 439.1 [M+H, 11B, 35Cl, 35Cl, 37Cl, 10%]+; HRMS(ES+) (m/z): [M+H]+ 
calcd. for C20H2111B35Cl3N2O2, 437.0756; found, 437.0738, error: 4.1 ppm. 
(Phenyl)(p-tolyl)borinic acid (6a): To an oven-dried Schlenk flask under 
N2 was added p-tolylmagnesium bromide (1.0 M in THF, 2.02 mL, 
2.02 mmol) in anhydrous THF (5 mL). Phenylboronic acid pinacol ester 
(0.41 g, 2.00 mmol) in anhydrous THF (5 mL) was added dropwise to the 
reaction mixture and stirred at room temperature for 3 h. 1M HCl (10 mL) 
was then added and stirred for 30 mins to quench the reaction. The 
reaction mixture was extracted with EtOAc (3 x 10 mL), washed with brine 
(1 x 10 mL), dried over MgSO4, filtered and evaporated in vacuo. The crude 
product was then purified by flash column chromatography (EtOAc/n-
hexane, 2:23) to give 6a as a colourless oil (0.18 g, 45%). 1H NMR 
(300 MHz, CDCl3): δ = 7.72 (d, J = 7.8 Hz, 2H, B-Ph(o)), 7.64 (d, J = 7.8 
Hz, 2H, B-Ar(o)), 7.32-7.47 (m, 3H, B-Ph(m/p)), 7.19 (d, J = 7.8 Hz, 2H, B-
Ar(m)), 5.74 (br s, 1H, OH), 2.33 ppm (s, 3H, CH3); 13C NMR (75 MHz, 
CDCl3): δ = 141.4 (B-Ar(p)), 135.0 (B-Ph(o)), 134.6 (B-Ar(o)), 130.9 (B-
Ph(p)), 128.8 (B-Ar(m)), 127.9 (B-Ph(m)), 21.7 ppm (CH3), B-Ar(i) and B-
Ph(i) quaternary signals not observed; MS(ES-) (m/z): 195.1 [M-H, 11B, 
25%]-; HRMS(ES-) (m/z): [M-H]- calcd. for  C13H1211BO, 195.0987; found, 
195.0973, error: 7.2 ppm. 
5-Acetyl-6-amino-2-(phenyl)-2-(p-tolyl)-4-(trichloromethyl)-2,3-
dihydro-1,3,2-oxazaborinin-1-ium-2-uide (NBC33): (Z)-2-Acetyl-3-
amino-4,4,4-trichlorobut-2-enamide (0.40 g, 1.65 mmol) was added to a 
solution of 6a (0.13 g, 0.66 mmol) in anhydrous THF (5 mL). The mixture 
was stirred at 50 oC under N2 for 16 h. The mixture was concentrated in 
vacuo and purified by flash column chromatography (EtOAc/n-hexane, 
2:23). The collected fractions were combined, evaporated in vacuo and 
stirred in cold n-hexane (15 mL) for 30 min. The precipitate was then 
filtered and dried under vacuum to give NBC33 as a yellow solid (4.9 mg, 
2%). mp: 141-143 oC; 1H NMR (300 MHz, CDCl3): δ = 9.25 (br s, 1H, 
CONH2), 7.59 (br s, 1H, Cl3C(NH)C=C), 7.40 (d, J = 6.0 Hz, 2H, B-Ph(o)), 
7.23-7.34 (m, 5H, B-Ph(m/p) & B-Ar(o)), 7.12 (d, J = 7.8 Hz, 2H, B-Ar(m)), 
5.94 (br s, 1H, CONH2), 2.34 (s, 3H, CH3), 2.31 ppm (s, 3H, CH3); 13C NMR 
(75 MHz, CDCl3): δ = 192.8 (CH3CO), 163.9 (Cl3C(NH)C=C), 160.3 
(CONH2), 131.1 (B-Ar(p)), 126.8 (B-Ph(o)), 126.6 (B-Ar(o)), 123.0 (B-
Ar(m)), 122.1 (B-Ph(m)), 121.5 (B-Ph(p)), 92.7 (Cl3C(NH)C=C), 89.2 
(CCl3), 28.7 (CH3CO), 16.0 ppm (CH3), B-Ar(i) and B-Ph(i) quaternary 
signals not observed; MS(ES-) (m/z): 420.2 [M-H, 10B, 35Cl, 35Cl, 35Cl, 12%]-, 
421.1 [M-H, 11B, 35Cl, 35Cl, 35Cl, 80%]-, 422.2 [M-H, 10B, 35Cl, 35Cl, 37Cl, 
33%]-, 423.2 [M-H, 11B, 35Cl, 35Cl, 37Cl, 100%]-, 424.1 [M-H, 10B, 35Cl, 37Cl, 
37Cl, 13%]-, 425.1 [M-H, 11B, 35Cl, 37Cl, 37Cl, 24%]-; HRMS(ES+) (m/z): 
[M+H]+ calcd. for C19H1911B35Cl3N2O2, 423.0600; found, 423.0605, error: 
1.2 ppm. 
General procedure for synthesis of 2,2-bisaryl-1,3,2-oxazaborines: 
Using an adapted procedure,[28] to an oven-dried Schlenk flask under N2 
was added magnesium turnings (2.2 eq), anhydrous THF (5 mL) and a 
small crystal of I2. The reaction was stirred at 40 oC for 30 mins until 
complete decolourisation. A solution of aryl bromide (2 eq) and B(OMe)3 
(1 eq) in anhydrous THF (5 mL) was then added dropwise to the reaction 
mixture and then stirred for an additional 3 h at 40 oC. After cooling to room 
temperature, 1M HCl (10 mL) was added and stirred for 30 mins to quench 
the reaction. The reaction mixture was extracted with EtOAc (3 x 10 mL), 
washed with brine (1 x 10 mL), dried over MgSO4, filtered and evaporated 
in vacuo to give the corresponding crude bisarylborinic acid, typically as a 
solid. (Z)-4-Amino-5,5,5-trichloropent-3-en-2-one (1.5 eq) was then added 
to crude bisarylborinic acid (1 eq) in anhydrous THF (5 mL). The reaction 
was stirred at 50 oC for 16 h under N2. The reaction mixture was 
concentrated and purified by flash column chromatography using the 
indicated solvent system. Collected fractions were evaporated in vacuo 
and stirred in the minimum amount of cold n-hexane for 30 mins to induce 
precipitation. The precipitate was then filtered and dried under vacuum to 
give the corresponding oxazaborine product. Percentage yields are 
reported over two steps. 
2,2-Bis(4-fluorophenyl)-6-methyl-4-(trichloromethyl)-2,3-dihydro-
1,3,2-oxazaborinin-1-ium-2-uide (NBC35): EtOAc/n-hexane, 1:9. 
Reaction scale: B(OMe)3 (0.56 mL, 5.00 mmol), 1-bromo-4-fluorobenzene 
(1.10 mL, 10 mmol) and magnesium turnings (0.27 g, 11 mmol) gives 
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bis(4-fluorophenyl)borinic acid (1.20 g, quant.). Bis(4-fluorophenyl)borinic 
acid (1.20 g, 5.50 mmol) and (Z)-4-amino-5,5,5-trichloropent-3-en-2-one 
(0.89 g, 4.40 mmol) gives NBC35 as a yellow solid (0.22 g, 12% over two 
steps). mp: 130-131 oC; 1H NMR (400 MHz, CDCl3): δ = 7.31 (dd ~ t, 3JHH 
~ 4JHF = 6.6 Hz, 4H, B-Ar(o)), 7.00 (t, 3JHH ~ 3JHF = 8.4 Hz, 4H, B-Ar(m)), 
5.83 (s, 1H, Cl3C(NH)C=CH), 2.25 ppm (s, 3H, CH3CO), NH signal is 
overlapping with triplet at 7.31 ppm; 13C NMR (100 MHz, CDCl3): δ = 186.5 
(CH3CO), 166.1 (Cl3C(NH)C=CH), 162.6 (d, 1JCF = 242.6 Hz, B-Ar(p)), 
133.4 (d, 3JCF = 27.6 Hz, B-Ar(o)), 114.4 (d, 2JCF = 77.2 Hz, B-Ar(m)), 92.8 
(CCl3), 92.0 (Cl3C(NH)C=CH), 24.9 ppm (CH3CO), B-Ar(i) quaternary 
signal not observed; 11B{1H} NMR (128 MHz, CDCl3): δ = 4.11 ppm; 
19F{1H} NMR (376 MHz, CDCl3): δ = -116.1 ppm; MS(ES-) (m/z): 399.1 [M-
H, 10B, 35Cl, 35Cl, 35Cl, 14%]-, 400.1 [M-H, 11B, 35Cl, 35Cl, 35Cl, 70%]-, 401.1 
[M-H, 10B, 35Cl, 35Cl, 37Cl, 40%]-, 402.1 [M-H, 11B, 35Cl, 35Cl, 37Cl, 100%]-, 
403.1 [M-H, 10B, 35Cl, 37Cl, 37Cl, 15%]-, 404.1 [M-H, 11B, 35Cl, 37Cl, 37Cl, 
33%]-; HRMS(ES-) (m/z): [M-H]- calcd. for C17H1211B35Cl319F2NO, 
400.0051; found, 400.0048, error: 0.7 ppm. 
2,2-Bis(4-chlorophenyl)-6-methyl-4-(trichloromethyl)-2,3-dihydro-
1,3,2-oxazaborinin-1-ium-2-uide (NBC36): EtOAc/n-hexane, 1:9. 
Reaction scale: B(OMe)3 (0.28 mL, 2.50 mmol), 1-bromo-4-chlorobenzene 
(0.96 g, 5.00 mmol) and magnesium turnings (0.13 g, 5.50 mmol) gives 
bis(4-chlorophenyl)borinic acid (0.71 g, 57%). Bis(4-chlorophenyl)borinic 
acid (0.71 g, 2.85 mmol) and (Z)-4-amino-5,5,5-trichloropent-3-en-2-one 
(0.86 g, 4.27 mmol) gives NBC36 as a yellow solid (0.38 g, 17% over two 
steps). mp: 106-107 oC; 1H NMR (400 MHz, CDCl3): δ = 7.25 (br s, 1H, 
NH), 7.19 (br s, 8H, B-Ar(o/m)), 5.76 (s, 1H, Cl3C(NH)C=CH), 2.18 ppm (s, 
3H, CH3CO); 13C NMR (100 MHz, CDCl3): δ = 186.7 (CH3CO), 166.3 
(Cl3C(NH)C=CH), 133.2 (B-Ar(o)), 133.1 (B-Ar(p)), 127.8 (B-Ar(m)), 92.7 
(CCl3), 92.2 (Cl3C(NH)C=CH), 24.8 ppm (CH3CO), B-Ar(i) quaternary 
signal not observed; 11B{1H} NMR (128 MHz, CDCl3): δ = 3.82 ppm; 
MS(ES-) (m/z): 431.0 [M-H, 10B, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 13%]-, 432.0 [M-
H, 11B, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 75%]-, 433.0 [M-H, 10B, 35Cl, 35Cl, 35Cl, 
35Cl, 37Cl, 42%]-, 434.0 [M-H, 11B, 35Cl, 35Cl, 35Cl, 35Cl, 37Cl, 100%]-, 435.0 
[M-H, 10B, 35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 25%]-, 436.0 [M-H, 11B, 35Cl, 35Cl, 35Cl, 
37Cl, 37Cl, 88%]-, 437.0 [M-H, 10B, 35Cl, 35Cl, 37Cl, 37Cl, 37Cl, 12%]-, 438.0 
[M-H, 11B, 35Cl, 35Cl, 37Cl, 37Cl, 37Cl, 30%]-; HRMS(ES-) (m/z): [M-H]- calcd. 
for C17H1211B35Cl5NO, 431.9460; found, 431.9460, error: 0.0 ppm. 
6-Methyl-4-(trichloromethyl)-2,2-bis(4-(trifluoromethyl)phenyl)-2,3-
dihydro-1,3,2-oxazaborinin-1-ium-2-uide (NBC37): EtOAc/n-hexane, 
1:19. Reaction scale: B(OMe)3 (0.28 mL, 2.50 mmol), 4-
bromobenzotrifluoride (0.70 mL, 5.00 mmol) and magnesium turnings 
(0.13 g, 5.50 mmol) gives bis(4-trifluorophenyl)borinic acid (0.81 g, quant.). 
Bis(4-trifluorophenyl)borinic acid (0.81 g, 2.55 mmol) and (Z)-4-amino-
5,5,5-trichloropent-3-en-2-one (0.77 g, 3.83 mmol) gives NBC37 as a 
yellow solid (0.43 g, 33% over two steps). mp: 103-105 oC; 1H NMR 
(400 MHz, CDCl3): δ = 7.56 (d, J = 7.6 Hz, 4H, B-Ar(m)), 7.46 (d, J = 7.6 
Hz, 4H, B-Ar(o)), 7.41 (br s, 1H, NH), 5.89 (s, 1H, Cl3C(NH)C=CH), 
2.30 ppm (s, 3H, CH3CO); 13C NMR (100 MHz, CDCl3): δ = 187.1 (CH3CO), 
166.7 (Cl3C(NH)C=CH), 131.8 (B-Ar(o)), 129.2 (q, 2JCF = 31.3 Hz, B-Ar(p)), 
124.7 (q, 1JCF = 270.2 Hz, CF3), 124.4 (q, 3JCF = 3.6 Hz, B-Ar(m)), 92.7 
(Cl3C(NH)C=CH), 24.8 ppm (CH3CO), B-Ar(i) and CCl3 quaternary signals 
not observed; 11B{1H} NMR (128 MHz, CDCl3): δ = 3.56 ppm; 19F{1H} NMR 
(376 MHz, CDCl3): δ = -62.4 ppm; MS(ES-) (m/z): 499.1 [M-H, 10B, 35Cl, 
35Cl, 35Cl, 22%]-, 500.1 [M-H, 11B, 35Cl, 35Cl, 35Cl, 75%]-, 501.1 [M-H, 10B, 
35Cl, 35Cl, 37Cl, 45%]-, 502.1 [M-H, 11B, 35Cl, 35Cl, 37Cl, 100%]-, 503.1 [M-H, 
10B, 35Cl, 37Cl, 37Cl, 12%]-, 504.1 [M-H, 11B, 35Cl, 37Cl, 37Cl, 22%]-; 
HRMS(ES-) (m/z): [M-H]- calcd. for C19H1211B35Cl319F6NO, 499.9987; found, 
499.9990, error: 0.6 ppm. 
2,2-Bis(4-methylphenyl)-6-methyl-4-(trichloromethyl)-2,3-dihydro-
1,3,2-oxazaborinin-1-ium-2-uide (NBC38): EtOAc/n-hexane, 1:19. 
Reaction scale: B(OMe)3 (0.28 mL, 2.50 mmol), 4-bromotoluene (0.62 mL, 
5.00 mmol) and magnesium turnings (0.13 g, 5.50 mmol) gives bis(4-
methylphenyl)borinic acid (0.44 g, 42%). Bis(4-methylphenyl)borinic acid 
(0.44 g, 2.11 mmol) and (Z)-4-amino-5,5,5-trichloropent-3-en-2-one (0.64 
g, 3.16 mmol) gives NBC38 as a yellow solid (68.8 mg, 4% over two steps). 
mp: 105-107 oC; 1H NMR (400 MHz, CDCl3): δ = 7.41 (br s, 1H, NH), 7.28 
(d, J = 7.2 Hz, 4H, B-Ar(o)), 7.13 (d, J = 7.2 Hz, 4H, B-Ar(m)), 5.77 (s, 1H, 
Cl3C(NH)C=CH), 2.34 (s, 6H, CH3 x 2), 2.23 ppm (s, 3H, CH3CO); 13C 
NMR (100 MHz, CDCl3): δ = 186.2 (CH3CO), 136.3 (B-Ar(p)), 131.9 (B-
Ar(o)), 128.4 (B-Ar(m)), 91.5 (Cl3C(NH)C=CH), 24.9 (CH3CO), 21.5 ppm 
(CH3), B-Ar(i) and Cl3C(NH)C=CH quaternary signals not observed; 
11B{1H} NMR (128 MHz, CDCl3): δ = 4.61 ppm; MS(ES-) (m/z): 392.1 [M-
H, 11B, 35Cl, 35Cl, 35Cl, 100%]-, 393.1 [M-H, 10B, 35Cl, 35Cl, 37Cl, 20%]-, 394.1 
[M-H, 11B, 35Cl, 35Cl, 37Cl, 88%]-, 395.1 [M-H, 10B, 35Cl, 37Cl, 37Cl, 21%]-, 
396.1 [M-H, 11B, 35Cl, 37Cl, 37Cl, 22%]-; MS(ES+) (m/z): 301.2 [M-Tolyl, 10B, 
35Cl, 35Cl, 35Cl, 75%]+, 302.1 [M-Tolyl, 11B, 35Cl, 35Cl, 35Cl, 90%]+, 303.1 [M-
Tolyl, 10B, 35Cl, 35Cl, 37Cl, 28%]+, 304.1 [M-Tolyl, 11B, 35Cl, 35Cl, 37Cl, 
100%]+, 305.1 [M-Tolyl, 10B, 35Cl, 37Cl, 37Cl, 16%]+, 306.0 [M-Tolyl, 11B, 35Cl, 
37Cl, 37Cl, 25%]+; HRMS(ES-) (m/z): [M-H]- calcd. for C19H1811B35Cl3NO, 
392.0553; found, 392.0555, error: 0.6 ppm. 
2,2-Bis(3,4-dichlorophenyl)-6-methyl-4-(trichloromethyl)-2,3-
dihydro-1,3,2-oxazaborinin-1-ium-2-uide (NBC39): EtOAc/n-hexane, 
1:19. Reaction scale: B(OMe)3 (0.28 mL, 2.50 mmol), 4-bromo-1,2-
dichlorobenzene (0.64 mL, 5.00 mmol) and magnesium turnings (0.13 g, 
5.50 mmol) gives bis(3,4-dichlorophenyl)borinic acid (0.92 g, 58%). 
Bis(3,4-dichlorophenyl)borinic acid (0.92 g, 2.88 mmol) and (Z)-4-amino-
5,5,5-trichloropent-3-en-2-one (0.87 g, 4.32 mmol) gives NBC39 as a 
cream solid (0.71 g, 43% over two steps). mp: 109-110 oC; 1H NMR (400 
MHz, CDCl3): δ = 7.37 (s, 2H, B-Ar-H2), 7.36 (d, J = 7.2 Hz, 2H, B-Ar-H5), 
7.10 (d, J = 8.0 Hz, 2H, B-Ar-H6), 5.88 (s, 1H, Cl3C(NH)C=CH), 2.28 ppm 
(s, 3H, CH3CO), NH signal is observed but overlapping with CHCl3 at 7.26 
ppm; 13C NMR (100 MHz, CDCl3): δ = 187.1 (CH3CO), 166.7 
(Cl3C(NH)C=CH), 133.5 (B-Ar-C6), 132.1 (B-Ar-C3), 131.1 (B-Ar-C4), 
130.9 (B-Ar-C2), 129.9 (B-Ar-C5), 92.8 (Cl3C(NH)C=CH), 92.5 (CCl3), 24.9 
ppm (CH3CO), B-Ar-C1 quaternary signal not observed; 11B{1H} NMR 
(128 MHz, CDCl3): δ = 3.10 ppm; MS(ES-) (m/z): 499.9 [M-H, 11B, 35Cl, 
35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 45%]-, 500.9 [M-H, 10B, 35Cl, 35Cl, 35Cl, 35Cl, 
35Cl, 35Cl, 37Cl, 22%]-, 501.9 [M-H, 11B, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 37Cl, 
100%]-, 502.9 [M-H, 10B, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 50%]-, 503.9 
[M-H, 11B, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 98%]-, 504.9 [M-H, 10B, 35Cl, 
35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 37Cl, 23%]-, 505.9 [M-H, 11B, 35Cl, 35Cl, 35Cl, 35Cl, 
37Cl, 37Cl, 37Cl, 63%]-, 506.9 [M-H, 10B, 35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 37Cl, 37Cl, 
10%]-, 507.9 [M-H, 11B, 35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 37Cl, 37Cl, 21%]-; 
HRMS(ES-) (m/z): [M-H]- calcd. for C17H1011B35Cl7NO, 499.8681; found, 
499.8681, error: 0.0 ppm. 
5-Acetyl-6-amino-2,2-bis(3-chloro-4-methylphenyl)-4-
(trichloromethyl)-2,3-dihydro-1,3,2-oxazaborinin-1-ium-2-uide 
(NBC40): Using an adapted procedure,[29] iPrMgCl (2.0 M in THF, 1.21 mL, 
2.42 mmol) was added dropwise to a solution of 2-chloro-4-iodotoluene 
(0.28 mL, 1.98 mmol) in anhydrous THF (5 mL) in an oven-dried Schlenk 
flask under N2. The reaction was stirred at 0oC for 5h. B(OMe)3 (0.10 mL, 
0.92 mmol) was then added and the reaction mixture was stirred overnight 
allowing to warm to room temperature. 3M HCl (10 mL) was added and 
the reaction mixture was extracted with EtOAc (3 x 10 mL), washed with 
brine (1 x 10 mL), dried over MgSO4, filtered and evaporated in vacuo to 
give crude bis(3-chloro-4-methylphenyl)borinic acid as a cream solid in 
quantitative yield. To a portion of this intermediate (0.20 g, 0.72 mmol) in 
anhydrous THF (5 mL) was added (Z)-2-acetyl-3-amino-4,4,4-trichlorobut-
2-enamide (0.26 g, 1.08 mmol). The reaction was stirred at 50 oC for 16 h 
under N2. The reaction mixture was concentrated and purified by flash 
column chromatography (EtOAc/n-hexane, 1:4). Collected fractions were 
evaporated in vacuo and stirred in the minimum amount of cold n-hexane 
for 30 mins to induce precipitation. The precipitate was then filtered and 
dried under vacuum to give NBC40 as a white solid (41.4 mg, 11%). mp: 
147-148 oC; 1H NMR (300 MHz, CDCl3): δ = 11.22 (br s, 1H, 
Cl3C(NH)C=C), 7.38 (s, 2H, B-Ar-H2), 7.18 (d, J = 7.8 Hz, 2H, B-Ar-H6), 
7.10 (d, J = 7.2 Hz, 2H, B-Ar-H5), 6.16 (br s, 1H, CONH2), 5.89 (br s, 1H, 
CONH2), 2.32 (s, 6H, CH3 x 2), 2.26 ppm (s, 3H, CH3CO); MS(ES-) (m/z): 
502.1 [M-H, 10B, 35Cl, 35Cl, 35Cl, 35Cl, 35Cl, 10%]-, 503.1 [M-H, 11B, 35Cl, 35Cl, 
35Cl, 35Cl, 35Cl, 42%]-, 504.1 [M-H, 10B, 35Cl, 35Cl, 35Cl, 35Cl, 37Cl, 27%]-, 
505.1 [M-H, 11B, 35Cl, 35Cl, 35Cl, 35Cl, 37Cl, 100%]-, 506.1 [M-H, 10B, 35Cl, 
35Cl, 35Cl, 37Cl, 37Cl, 24%]-, 507.1 [M-H, 11B, 35Cl, 35Cl, 35Cl, 37Cl, 37Cl, 45%]-, 
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508.1 [M-H, 10B, 35Cl, 35Cl, 37Cl, 37Cl, 37Cl, 14%]-, 509.1 [M-H, 11B, 35Cl, 35Cl, 
37Cl, 37Cl, 37Cl, 13%]-; HRMS(ES-) (m/z): [M-H]- calcd. for 
C20H1711B35Cl5N2O2, 502.9831; found, 502.9833, error: 0.4 ppm. 
3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl) 
borane (AN0128): Prepared according to a previously published 
method.[29] iPrMgCl (2.0 M in THF, 2.42 mL, 4.83 mmol) was added 
dropwise to a solution of 2-chloro-4-iodotoluene (0.56 mL, 3.96 mmol) in 
anhydrous THF (5 mL) in an oven-dried Schlenk flask under N2. The 
reaction was stirred at 0 oC for 5 h. B(OMe)3 (0.21 mL, 1.84 mmol) was 
then added and the reaction mixture was stirred overnight allowing to warm 
to room temperature. 3M HCl (10 mL) was then added and the reaction 
mixture was extracted with EtOAc (3 x 10 mL), washed with brine (1 x 10 
mL), dried over MgSO4, filtered and evaporated in vacuo to give crude 
bis(3-chloro-4-methylphenyl)borinic acid as a cream solid in quantitative 
yield. A portion of this intermediate (0.50 g, 1.79 mmol) was dissolved in 
EtOH (5 mL) and heated to reflux. 3-Hydroxypicolinic acid (0.20 g, 1.43 
mmol) was added in portions to the hot solution and after the last addition, 
the reaction mixture was stirred at reflux for 15 mins. The reaction was 
then cooled, resulting in the precipitation of product from the solution. The 
reaction mixture was partially concentrated and the precipitate was re-
crystallised in EtOH to give AN0128 as a white solid (0.30 g, 53%). mp: 
166-167 oC (lit. 165.0-166.5 oC)[29]; 1H NMR (300 MHz, DMSO-d6): δ = 
12.17 (br s, 1H, OH), 8.58 (t, J = 3.2 Hz, 1H, Py-H12), 7.93 (d, J = 3.0 Hz, 
2H, Py-H10,11), 7.22 (d, J = 7.5 Hz, 2H, B-Ar-H6), 7.20 (s, 2H, B-Ar-H2), 
7.11 (d, J = 7.5 Hz, 2H, B-Ar-H5), 2.27 ppm (s, 6H, CH3 x 2); 13C NMR 
(100 MHz, DMSO-d6): δ = 162.2 (COO), 156.2 (Py-C9), 134.2 (Py-C8), 
134.0 (Py-C12), 133.0 (B-Ar-C4), 132.1 (B-Ar-C3), 131.9 (B-Ar-C6), 131.5 
(Py-C11), 130.7 (B-Ar-C5), 130.5 (B-Ar-C2), 127.5 (Py-C10), 19.4 ppm 
(CH3), B-Ar-C1 quaternary signal not observed; 11B{1H} NMR (128 MHz, 
DMSO-d6): δ = 6.76 ppm; MS(ES-) (m/z): 397.1 [M-H, 10B, 35Cl, 35Cl, 22%]-, 
398.1 [M-H, 11B, 35Cl, 35Cl, 100%]-, 399.1 [M-H, 10B, 35Cl, 37Cl, 63%]-, 400.1 
[M-H, 11B, 35Cl, 37Cl, 67%]-, 401.1 [M-H, 10B, 37Cl, 37Cl, 17%]-; HRMS(ES-) 
(m/z): [M-H]- calcd. for C20H1511B35Cl2NO3, 398.0528; found, 398.0526, 
error: 0.5 ppm. All data were in agreement with literature values.[29]  
3-(1-Amino-2,2,2-trifluoroethylidene)pentane-2,4-dione (8): Using a 
previously reported procedure,[33] CF3CN was slowly generated by drop-
wise addition of a solution of trifluoroacetic anhydride (8.33 mL, 59.93 
mmol) in anhydrous pyridine (40 mL) to a solution of trifluoroacetamide 
(6.77 g, 59.93 mmol) in anhydrous pyridine (20 mL) under N2 in a three-
neck round-bottom flask equipped with a N2 gas inlet and gas outlet. The 
gas outlet was connected to a two-neck round-bottom flask containing a 
solution of acetylacetone (0.51 mL, 4.99 mmol) and Zn(acac)2 (14.1 mg, 
0.050 mmol) in anhydrous DCM (10 mL) that was equipped with a dry ice 
condenser connected to a bubbler outlet. CF3CN was bubbled into the 
stirring solution at room temperature for several hours until complete 
consumption of the trifluoroacetic anhydride solution. The reaction was 
further stirred at room temperature for 16 h. The reaction mixture was 
extracted with DCM (3 x 10 mL), washed with brine (1 x 10 mL), dried over 
MgSO4, filtered and evaporated in vacuo to give 8 as a white solid (0.86 g, 
88%). 1H NMR (400 MHz, CDCl3): δ = 2.46 (s, 3H, CH3CO), 2.18 ppm (s, 
3H, CH3CO); 13C NMR (100 MHz, CDCl3): δ = 202.1 (CH3CO), 196.4 
(CH3CO), 145.7 (q, 2JCF = 33 Hz, F3C(NH2)C=C), 120.2 (q, 1JCF = 276 Hz, 
CF3), 112.8 (F3C(NH2)C=C), 32.2 (q, 5JCF = 4 Hz, CH3CO cis to CF3), 29.2 
ppm (CH3CO); 19F{1H} NMR (376 MHz, CDCl3): δ = -66.4 ppm. All data 
were in agreement with literature values.[34]  
(Z)-4-Amino-5,5,5-trifluoropent-3-en-2-one (10): Using an adapted 
procedure,[34] 8 (2.54 g, 13.02 mmol) was dissolved in EtOH (10 mL) and 
a saturated solution of K2CO3 (20 mL) was added. The reaction was stirred 
at 50 oC for 24 h. The reaction mixture was then extracted with CHCl3 (3 x 
10 mL), washed with brine (1 x 10 mL), dried over MgSO4, filtered and 
evaporated in vacuo. The crude mixture was purified by flash column 
chromatography (1:4, EtOAc/n-hexane) to give 10 as an orange solid (0.42 
g, 27% over two steps). 1H NMR (400 MHz, CDCl3): δ = 5.52 (s, 1H, 
F3C(NH2)C=CH), 2.18 ppm (s, 3H, CH3CO); 13C NMR (100 MHz, CDCl3): 
δ = 199.6 (CH3CO), 147.1 (q, 2JCF = 33.3 Hz, F3C(NH2)C=CH), 120.4 (q, 
1JCF = 274 Hz, CF3), 94.1 (q, 3JCF = 3.7 Hz, F3C(NH2)C=CH), 30.5 ppm 
(CH3CO); 19F{1H} NMR (376 MHz, CDCl3): δ = -71.8 ppm. All data were in 
agreement with literature values.[34]    
6-Methyl-2,2-diphenyl-4-(trifluoromethyl)-2,3-dihydro-1,3,2-
oxazaborinin-1-ium-2-uide (NBC41): Using an adapted procedure,[37] 10 
(0.29 g, 1.92 mmol) was added to a solution of DPBA (0.43 g, 1.23 mmol) 
in anhydrous THF (5 mL). The reaction mixture was stirred at 50 oC under 
Ar for 16 h. The reaction mixture was then concentrated and purified by 
flash column chromatography (3:20, EtOAc/n-hexane) to give NBC41 as a 
yellow solid (0.34 g, 88%). mp: 96-97 oC (lit. 99-100 oC)[37]; 1H NMR (400 
MHz, CDCl3): δ = 7.14-7.31 (m, 10H, B-Ph x 2), 6.95 (br s, 1H, NH), 5.44 
(d, 4JNH,H = 2.0 Hz, 1H, F3C(NH)C=CH), 2.17 ppm (s, 3H, CH3CO); 13C 
NMR (100 MHz, CDCl3): δ = 188.3 (CH3CO), 156.7 (q, 2JCF = 35.0 Hz, 
F3C(NH)C=CH), 131.8 (B-Ph(o)), 127.6 (B-Ph(m)), 127.1 (B-Ph(p)), 118.8 
(q, 1JCF = 276.7 Hz, CF3), 91.6 (F3C(NH)C=CH), 24.9 ppm (CH3CO); 
11B{1H} NMR (128 MHz, CDCl3): δ = 4.37 ppm; 19F{1H} NMR (376 MHz, 
CDCl3): δ = -72.9 ppm; MS(ES-) (m/z): 316.11 [M-H, 98%]-; MS(ES+) (m/z): 
340.11 [M+Na, 100%]+; HRMS(ES-) (m/z): [M+Na]- calcd. for 
C17H1511BF3NO, 340.1091; found, 340.1085, error: 1.8 ppm. All data were 
in agreement with literature values.[37]  
(Z)-2-Acetyl-3-amino-4,4,4-trifluorobut-2-enamide (9): CF3CN was 
slowly generated by drop-wise addition of a solution of trifluoroacetic 
anhydride (8.26 mL, 59.41 mmol) in anhydrous pyridine (40 mL) to a 
solution of trifluoroacetamide (6.71 g, 59.41 mmol) in anhydrous pyridine 
(20 mL) under N2 in a three-neck round-bottom flask equipped with a N2 
gas inlet and gas outlet. The gas outlet was connected to a two-neck 
round-bottom flask containing a solution of acetoacetamide (1.00 g, 9.90 
mmol) and Zn(acac)2 (27.9 mg, 0.099 mmol) in anhydrous DCM (10 mL) 
that was equipped with a dry ice condenser connected to a bubbler outlet. 
CF3CN was bubbled into the stirring solution at room temperature for 
several hours until complete consumption of the trifluoroacetic anhydride 
solution. The reaction was further stirred at room temperature for 16 h. The 
reaction mixture was extracted with EtOAc (5 x 50 mL), washed with brine 
(3 x 50 mL), dried over MgSO4, filtered and evaporated in vacuo. Et2O (10 
mL) was added to induce precipitation and the precipitate was filtered, 
washed with additional Et2O and dried to give 9 as a white solid (1.52 g, 
78%). mp: 192-193 oC; 1H NMR (400 MHz, CDCl3): δ = 9.06 (br s, 2H, 
NH2), 7.75 (br s, 1H, CONH2), 7.40 (br s, 1H, CONH2), 2.18 ppm (s, 3H, 
CH3CO); 13C NMR (100 MHz, CDCl3): δ = 196.5 (CH3CO), 168.3 (CONH2), 
144.9 (q, 2JCF = 32.3 Hz, F3C(NH2)C=C), 120.3 (q, 1JCF = 277.7 Hz, CF3), 
107.0 (F3C(NH2)C=C), 28.0 ppm (CH3CO); 19F{1H} NMR (376 MHz, 
CDCl3): δ = -65.4 ppm; MS(ES-) (m/z): 195.04 [M-H, 100%]-; MS(ES+) 
(m/z): 219.03 [M+Na, 100%]+; HRMS(ES-) (m/z): [M+Na]- calcd. for 
C6H7F3N2O2, 219.0352; found, 219.0346, error: 2.7 ppm. 
5-Acetyl-6-amino-2,2-diphenyl-4-(trifluoromethyl)-2,3-dihydro-1,3,2-
oxazaborinin-1-ium-2-uide (NBC42): 9 (0.72 g, 3.69 mmol) was added 
to a solution of DPBA (0.43 g, 1.23 mmol) in anhydrous THF (5 mL). The 
reaction mixture was stirred at 50 oC under Ar for 16 h. The reaction 
mixture was then concentrated and purified by flash column 
chromatography (1:5, EtOAc/n-hexane). The collected fractions were 
combined, evaporated in vacuo and precipitated in n-hexane (10 mL) to 
give NBC42 as a white solid (0.28 g, 64%). mp: 118-120 oC; 1H NMR (300 
MHz, CDCl3): δ = 10.05 (br s, 1H, NH), 7.22-7.36 (m, 10H, B-Ph), 6.17 (br 
s, 1H, NH), 2.26 ppm (q, 6JHF = 2.1 Hz, 3H, CH3CO); 13C NMR (75 MHz, 
CDCl3): δ = 196.3 (CH3CO), 169.8 (CONH2), 156.7 (q, 2JCF = 34.6 Hz, 
F3C(NH)C=C), 131.8 (B-Ar(o)), 127.5 (B-Ar(m)), 127.0 (B-Ar(p)), 119.4 (q, 
1JCF = 280.0 Hz, CF3), 97.2 (F3C(NH)C=C), 30.5 ppm (q, 5JCF = 5.5 Hz, 
CH3CO), B-Ar(i) quaternary signal not observed; 11B{1H} NMR (128 MHz, 
CDCl3): δ = 2.55 ppm; 19F{1H} NMR (376 MHz, CDCl3): δ = -65.1 ppm; 
MS(ES-) (m/z): 227.0 [M-(BPh2)-H, 50%]-, 359.1 [M-H, 100%]-, 523.3 
[M+BPh2-H, 60%]-; MS(ES+) (m/z): 219.0 [M-BPh2+Na, 50%]+, 399.1 [M+K, 
60%]+, 219.0 [M+BPh2+Na, 40%]+, 563.2 [M+BPh2+K, 100%]+; 
HRMS(ES+) (m/z): [M+H]+ calcd. for C18H1711BF3N2O2, 361.1330; found, 
361.1338, error: 2.3 ppm. 
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Cell Culture 
Immortalized murine bone marrow-derived macrophages (iBMDMs) were 
cultured in DMEM, 10% fetal bovine serum (FBS), 100 U/ml penicillin and 
100 μg/ml streptomycin (PenStrep). Cells were seeded overnight at 0.75 x 
106 cells/ml and then stimulated with LPS (E.coli O26:B6, 1 µg/ml, 4 h), 
and then incubated with vehicle (0.5% DMSO) or drug as indicated (10 
µM) for 15 min before activation of NLRP3 using nigericin (10 µM, 60 min). 
IL-1β release was measured by a specific ELISA (R&D systems). 
Data presentation and statistical analysis 
Data are presented as mean values+standard error of the mean (s.e.m) of 
at least three separate experiments. Statistical analyses performed were 
one-way analysis of variance (ANOVA) with Dunnett’s multiple 
comparisons test post hoc. Accepted levels of significance were *P<0.05, 
***P<0.001. Statistical analyses were carried out using GraphPad Prism.  
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NLRP3 is a central regulator of sterile inflammation and its overactivation contributes to the progression of several important 
diseases, thus representing a therapeutic target for the treatment of sterile inflammatory disease. SAR analysis of a series of 
oxazaborine small molecules that inhibit NLRP3-dependent IL-1β release are reported, the results of which will aid the development 
of this new class of boron-based NLRP3 inflammasome inhibitors. 
